TNYA

Rating neutralTentativeAI Memo

Tenaya Therapeutics

As of 2026-10-15/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

Coverage is limited for this name, so the memo relies on a thinner evidence base.; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

TN-201 MyPEAK-1 interim data and pivotal-trial discussions • 2026-12-31

Base target: $0 / p=40% prob

Biggest risk

Both lead programs rely on small early-stage datasets. Disappointing follow-up, difficult regulatory requirements or funding needs could outweigh encouraging interim signals; the company’s stated runway extends only through Q3 2027 [#SEC-8K-2026-08-05].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Further clinical benefit with acceptable safety, coupled with workable pivotal-trial plans, could improve confidence in TN-201 and TN-401. Tenaya’s August update also reported a $10 million Alnylam collaboration upfront payment [#SEC-8K-2026-08-05].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-15

Base target

p=40%

Bull target

p=25%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

TN-301 Phase 2 start versus funding runway
Further clinical benefit with acceptable safety, coupled with workable pivotal-trial plans, could improve confidence in TN-201 and TN-401.
Tenaya’s August update also reported a $10 million Alnylam collaboration upfront payment [#SEC-8K-2026-08-05].

BearKey bullets

Cash runway was projected through Q3 2027, potentially ahead of or near the planned second-half 2027 TN-301 Phase 2 start [#SEC-8K-2026-08-05].
Q2 2026 net loss was $43.4 million, including a $21.8 million non-cash manufacturing-facility impairment; future manufacturing will depend partly on an external contractor [#SEC-8K-2026-08-05].
Small TN-201 and TN-401 cohorts may not establish durable benefit or an acceptable pivotal-trial design [#SEC-8K-2026-08-05].

WatchKey bullets

TN-201 MyPEAK-1 interim data and pivotal-trial discussions

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=40%)

Target spread vs base: +91% / -56%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $0 (p=40%)Bear Target: $0 (p=35%)

Commentary

The packet supplies no usable company-specific recent-news, social, options, short-interest or employee-sentiment measurements; zero fields denote unavailable data, not neutral readings. No verified recent analyst revisions or attributable post-release price reaction are available. The negative deterministic directional prior, binary trial outcomes and limited coverage favor monitoring rather than extrapolating the early data.

As of 2026-10-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

TN-301 Phase 2 start versus funding runway

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$0 / p=40% prob

Bear Target (Scenario probability)

$0 / p=35% prob

Analysis 2026-10-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
TN-201 MyPEAK-1 interim data and pivotal-trial discussions
Tenaya expects additional TN-201 data and an update on regulatory discussions in Q4 2026. Its earlier report described improvement in at least one hypertrophy and one symptom measure among six evaluable patients; the small dataset leaves durability, safety and trial-design questions open [#SEC-8K-2026-08-05] [#8-K-2026-08-05].
Prob 75.00% • Move 25.00% • Priced-in 30.00%
EVENT2026-12-31
TN-401 RIDGE-1 interim data and pivotal-trial discussions
Additional TN-401 data and a regulatory-planning update are expected in Q4 2026. The prior six-patient interim dataset showed a mean 64% reduction in premature ventricular contraction count, but durability and pivotal-trial feasibility remain unproven [#SEC-8K-2026-08-05].
Prob 75.00% • Move 25.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

TN-301 Phase 2 start versus funding runway
2027-12-31
Tenaya intends to initiate at least one TN-301 proof-of-activity Phase 2 trial in the second half of 2027. Its August update put cash at $78.1 million on June 30 and projected funding through Q3 2027, making financing and execution important ahead of the planned start [#SEC-8K-2026-08-05].
Prob 55% • Move 10% • Priced-in 15%

Risks

Cash runway was projected through Q3 2027, potentially ahead of or near the planned second-half 2027 TN-301 Phase 2 start [#SEC-8K-2026-08-05].
Q2 2026 net loss was $43.4 million, including a $21.8 million non-cash manufacturing-facility impairment; future manufacturing will depend partly on an external contractor [#SEC-8K-2026-08-05].
Small TN-201 and TN-401 cohorts may not establish durable benefit or an acceptable pivotal-trial design [#SEC-8K-2026-08-05].

Peers

Symbol	Summary
LXEO	Tenaya identifies Lexeo Therapeutics’ LX2020 as another clinical competitor to TN-401 in PKP2-associated ARVC. Its relevance does not extend automatically to TN-201 or TN-301 [#10-K-2026-03-11].
RCKT	Tenaya identifies Rocket Pharmaceuticals’ RP-A601 as a clinical competitor to TN-401 in PKP2-associated ARVC. This is a program-level comparator, not a whole-company valuation peer [#10-K-2026-03-11].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-15

Loading AI feed…

Symbol

Summary

LXEO

Tenaya identifies Lexeo Therapeutics’ LX2020 as another clinical competitor to TN-401 in PKP2-associated ARVC. Its relevance does not extend automatically to TN-201 or TN-301 [#10-K-2026-03-11].

RCKT

Tenaya identifies Rocket Pharmaceuticals’ RP-A601 as a clinical competitor to TN-401 in PKP2-associated ARVC. This is a program-level comparator, not a whole-company valuation peer [#10-K-2026-03-11].